Sympathetic nervous system function in renal hypertension

Meryem Tuncel, Robert Augustyniak, Weiguo Zhang, Robert D. Toto, Ronald G. Victor

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Hypertension is a common complication of chronic renal failure, accelerating the deterioration in renal function and constituting an important risk factor for the excessive cardiovascular morbidity and mortality. However, there are large gaps in our understanding of the pathogenesis and treatment of renal hypertension. Although this hypertension traditionally is thought to be largely volume dependent, an increasing body of literature suggests that there is an important sympathetic neural component. Microneuro-graphic studies have demonstrated sympathetic overactivity without baroreflex impairment in both hypertensive chronic hemodialysis patients as well as in those with less advanced renal insufficiency. In a small group of patients with moderate chronic renal insufficiency and renin-dependent hypertension, sympathetic overactivity was normalized during antihypertensive monotherapy with the angiotensin converting enzyme inhibitor enalapril, but exacerbated by antihypertensive therapy with the dihydropyridine calcium channel blocker amlodipine. These results implicate a potentially important role for the sympathetic nervous system in explaining recent trial data suggesting an added renoprotective effect of antihypertensive agents that block the renin-angiotensin system. Future clinical trials are needed to determine whether normalization of sympathetic activity should constitute an important therapeutic goal to improve renal and cardiovascular outcomes in patients with chronic renal failure.

Original languageEnglish (US)
Pages (from-to)229-236
Number of pages8
JournalCurrent Hypertension Reports
Volume4
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Renal Hypertension
Sympathetic Nervous System
Antihypertensive Agents
Hypertension
Chronic Kidney Failure
Kidney
Amlodipine
Enalapril
Baroreflex
Calcium Channel Blockers
Renin-Angiotensin System
Chronic Renal Insufficiency
Angiotensin-Converting Enzyme Inhibitors
Renin
Renal Insufficiency
Renal Dialysis
Therapeutics
Clinical Trials
Morbidity
Mortality

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Sympathetic nervous system function in renal hypertension. / Tuncel, Meryem; Augustyniak, Robert; Zhang, Weiguo; Toto, Robert D.; Victor, Ronald G.

In: Current Hypertension Reports, Vol. 4, No. 3, 2002, p. 229-236.

Research output: Contribution to journalArticle

Tuncel, Meryem ; Augustyniak, Robert ; Zhang, Weiguo ; Toto, Robert D. ; Victor, Ronald G. / Sympathetic nervous system function in renal hypertension. In: Current Hypertension Reports. 2002 ; Vol. 4, No. 3. pp. 229-236.
@article{ac585bd172254d0aac33e561ef47b012,
title = "Sympathetic nervous system function in renal hypertension",
abstract = "Hypertension is a common complication of chronic renal failure, accelerating the deterioration in renal function and constituting an important risk factor for the excessive cardiovascular morbidity and mortality. However, there are large gaps in our understanding of the pathogenesis and treatment of renal hypertension. Although this hypertension traditionally is thought to be largely volume dependent, an increasing body of literature suggests that there is an important sympathetic neural component. Microneuro-graphic studies have demonstrated sympathetic overactivity without baroreflex impairment in both hypertensive chronic hemodialysis patients as well as in those with less advanced renal insufficiency. In a small group of patients with moderate chronic renal insufficiency and renin-dependent hypertension, sympathetic overactivity was normalized during antihypertensive monotherapy with the angiotensin converting enzyme inhibitor enalapril, but exacerbated by antihypertensive therapy with the dihydropyridine calcium channel blocker amlodipine. These results implicate a potentially important role for the sympathetic nervous system in explaining recent trial data suggesting an added renoprotective effect of antihypertensive agents that block the renin-angiotensin system. Future clinical trials are needed to determine whether normalization of sympathetic activity should constitute an important therapeutic goal to improve renal and cardiovascular outcomes in patients with chronic renal failure.",
author = "Meryem Tuncel and Robert Augustyniak and Weiguo Zhang and Toto, {Robert D.} and Victor, {Ronald G.}",
year = "2002",
doi = "10.1007/s11906-002-0012-7",
language = "English (US)",
volume = "4",
pages = "229--236",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - Sympathetic nervous system function in renal hypertension

AU - Tuncel, Meryem

AU - Augustyniak, Robert

AU - Zhang, Weiguo

AU - Toto, Robert D.

AU - Victor, Ronald G.

PY - 2002

Y1 - 2002

N2 - Hypertension is a common complication of chronic renal failure, accelerating the deterioration in renal function and constituting an important risk factor for the excessive cardiovascular morbidity and mortality. However, there are large gaps in our understanding of the pathogenesis and treatment of renal hypertension. Although this hypertension traditionally is thought to be largely volume dependent, an increasing body of literature suggests that there is an important sympathetic neural component. Microneuro-graphic studies have demonstrated sympathetic overactivity without baroreflex impairment in both hypertensive chronic hemodialysis patients as well as in those with less advanced renal insufficiency. In a small group of patients with moderate chronic renal insufficiency and renin-dependent hypertension, sympathetic overactivity was normalized during antihypertensive monotherapy with the angiotensin converting enzyme inhibitor enalapril, but exacerbated by antihypertensive therapy with the dihydropyridine calcium channel blocker amlodipine. These results implicate a potentially important role for the sympathetic nervous system in explaining recent trial data suggesting an added renoprotective effect of antihypertensive agents that block the renin-angiotensin system. Future clinical trials are needed to determine whether normalization of sympathetic activity should constitute an important therapeutic goal to improve renal and cardiovascular outcomes in patients with chronic renal failure.

AB - Hypertension is a common complication of chronic renal failure, accelerating the deterioration in renal function and constituting an important risk factor for the excessive cardiovascular morbidity and mortality. However, there are large gaps in our understanding of the pathogenesis and treatment of renal hypertension. Although this hypertension traditionally is thought to be largely volume dependent, an increasing body of literature suggests that there is an important sympathetic neural component. Microneuro-graphic studies have demonstrated sympathetic overactivity without baroreflex impairment in both hypertensive chronic hemodialysis patients as well as in those with less advanced renal insufficiency. In a small group of patients with moderate chronic renal insufficiency and renin-dependent hypertension, sympathetic overactivity was normalized during antihypertensive monotherapy with the angiotensin converting enzyme inhibitor enalapril, but exacerbated by antihypertensive therapy with the dihydropyridine calcium channel blocker amlodipine. These results implicate a potentially important role for the sympathetic nervous system in explaining recent trial data suggesting an added renoprotective effect of antihypertensive agents that block the renin-angiotensin system. Future clinical trials are needed to determine whether normalization of sympathetic activity should constitute an important therapeutic goal to improve renal and cardiovascular outcomes in patients with chronic renal failure.

UR - http://www.scopus.com/inward/record.url?scp=0036616016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036616016&partnerID=8YFLogxK

U2 - 10.1007/s11906-002-0012-7

DO - 10.1007/s11906-002-0012-7

M3 - Article

C2 - 12003706

AN - SCOPUS:0036616016

VL - 4

SP - 229

EP - 236

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 3

ER -